NasdaqCM - Nasdaq Real Time Price USD

PainReform Ltd. (PRFX)

Compare

3.1500

-0.0200

(-0.63%)

At close: January 10 at 4:00:00 PM EST

3.0400

-0.11

(-3.49%)

After hours: January 10 at 6:18:02 PM EST

PainReform Faces Setback in Phase 3 Trial for PRF-110

PainReform ( (PRFX) ) has provided an update. PainReform announced that its Phase 3 clinical trial for PRF-110 did not meet its primary endpoint of providing effective postoperative pain relief over 72 hours, as data from the final 24-hour period could not be clarified. Despite this setback, the company is engaging in further R&D efforts to refine the drug’s pharmaco-kinetics and pharmaco-dynamics to potentially support future trials, reflecting their commitment to enhancing pain relief solution

TipRanks 13 days ago

PRFX
-0.63%
PainReform Provides Further Update on Phase 3 Clinical Trial of PRF-110

TEL AVIV, Israel, Dec. 27, 2024 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced an update regarding its Phase 3 clinical trial evaluating PRF-110 in post-surgical pain management of patients undergoing bunionectomy. PainReform previously disclosed initial topline data from its Phase 3 clinical trial in which it reported that it demonstrat

GlobeNewswire 14 days ago

PRFX
-0.63%
PainReform Announces Initial Topline Data for PRF-110 Phase 3 Clinical Trial

TEL AVIV, Israel, Nov. 20, 2024 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced the receipt of partial topline data from its contract research organization (CRO), Lotus Clinical Research ("Lotus"), for the Phase 3 clinical trial evaluating PRF-110 in post-surgical pain management of patients undergoing bunionectomy. Initial analysis of th

GlobeNewswire last month

PRFX
-0.63%
PainReform Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders’ Equity Requirement

This notification has no immediate effect on the listing or trading of PainReform’s ordinary shares on the Nasdaq Capital Market TEL AVIV, Israel, Nov. 07, 2024 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced that it has received a notification from the Listing Qualifications Department of the Nasdaq Stock Market LLC (“Nasdaq”) advising t

GlobeNewswire 2 months ago

PRFX
-0.63%
PainReform cut to Hold at Maxim amid ‘changed’ market dynamics

As previously reported, Maxim analyst Naz Rahman downgraded PainReform (PRFX) to Hold from Buy. The company is developing PRF-110 to treat post-operative pain and compete in the market with Exparel and Zynrelef, but market dynamics have recently changed, with a generic for Exparel – the market leader – having been approved in July 2024 and impacting the market opportunity for PainReform and its operational ramifications, the analyst tells investors in a research note. Maxim adds that PainReform

TipRanks 2 months ago

PRFX
-0.63%
PainReform Ltd. Confirms Sutures Compatibility in Human Clinical Trials for PRF-110

Positive Compatibility Results Reinforce Safety and Efficacy of PRF-110 in Post-Surgical Pain ManagementTEL AVIV, Israel, Sept. 11, 2024 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced positive findings regarding the compatibility of sutures in human clinical trials of its lead product, PRF-110. PRF-110 is designed to provide extended, no

GlobeNewswire 3 months ago

PRFX
-0.63%
Top Midday Decliners

Top Midday Decliners

PREMIUM
MT Newswires 3 months ago

PRFX
-0.63%
HPE
PainReform Announces Exercise of Warrants for $1.58 Million Gross Proceeds

TEL AVIV, Israel, Sept. 10, 2024 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced the entry into definitive agreements for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 989,300 ordinary shares of the Company originally issued in December 2023 and April 2024, having an exercise price of $4.80 per s

GlobeNewswire 3 months ago

PRFX
-0.63%
Upcoming Stock Splits This Week (September 9 to September 13) – Stay Invested

These are the upcoming stock splits for the week of September 9 to September 13, based on TipRanks’ Stock Splits Calendar. A stock split is a corporate action in which the company issues additional common shares to increase the number of outstanding shares. Accordingly, the stock price of the company’s shares decreases, which maintains the market capitalization before and after the split. In contrast, there are also reverse stock splits that reduce the number of outstanding shares (consolidate).

TipRanks 3 months ago

CPAMF

TTEK

BKSY
PainReform Bunionectomy Study Observations Confirm Optimal Delivery Method for PRF-110 in Bunionectomy Procedures

PRF-110 Demonstrates Superior Coverage and Stability in Surgical Wounds Findings Highlight PRF-110’s Competitive Edge Over Leading Pain Management Products TEL AVIV, Israel, Aug. 21, 2024 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced the successful determination of the optimal delivery method for PRF-110 in bunionectomy procedures. This

GlobeNewswire 4 months ago

PRFX
-0.63%
PainReform Announces Positive Safety Profile for PRF-110 in Phase 3 Bunionectomy Study

TEL AVIV, Israel, Aug. 20, 2024 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced encouraging early safety results from its ongoing Phase 3 bunionectomy study of PRF-110, the Company’s proprietary post-surgical pain formulation. The study, which has now completed full enrollment with a total of 443 patients across eight clinical sites in th

GlobeNewswire 4 months ago

PRFX
-0.63%
PainReform Provides Business Update for the Second Quarter of 2024

Reaches full enrollment in the second part of Phase 3 clinical trial of PRF-110 in bunionectomy Remains on track to announce top-line data in late 2024 New highly scalable manufacturing process expected to significantly enhance future commercialization efforts TEL AVIV, Israel, Aug. 15, 2024 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today provided

GlobeNewswire 4 months ago

PRFX
-0.63%
PainReform Announces Development and Successful Manufacturing of New Formulations Providing Anti-Inflammatory and Extended Analgesic Effects

New formulations designed to enhance postoperative recoveryTEL AVIV, Israel, Aug. 12, 2024 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, announces the successful development and manufacturing of new patented formulations of its extended postoperative pain relief therapy, PRF-110. These novel formulations may incorporate both the analgesic and an anti-i

GlobeNewswire 4 months ago

PRFX
-0.63%
PainReform Announces Favorable Safety Profile of PRF-110, Indicating Potential for Use in New Surgical Applications Requiring Higher Doses

TEL AVIV, Israel, Aug. 07, 2024 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced compelling safety data for its lead product candidate, PRF-110. This data, derived from pharmacokinetic (PK) studies in both herniorrhaphy and bunionectomy clinical trials, highlights PRF-110's promising safety profile, with maximum blood levels (Cmax) recorde

GlobeNewswire 5 months ago

PRFX
-0.63%
PainReform Ltd. Announces Favorable Wound Healing Data in Human Clinical Trials for PRF-110

PRF-110 promoted normal wound healing and prevented scar formation following surgical procedures Company reaffirms it is on track to report top-line results from the Phase 3 trial in the second half of 2024 TEL AVIV, Israel, Aug. 05, 2024 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, announces positive wound healing data from its human clinical trials

GlobeNewswire 5 months ago

PRFX
-0.63%
PainReform’s New Manufacturing Process Achieves Significant Benefits Including 18-Month Stability of PRF-110 at Room Temperature

New process expected to significantly bolster future commercialization effortsTEL AVIV, Israel, Aug. 01, 2024 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, announces a major advancement in the development of its lead asset, PRF-110. The Company's new highly scalable manufacturing process, for which it recently filed a new patent, has enabled PRF-110 to

GlobeNewswire 5 months ago

PRFX
-0.63%
PainReform Files Patent Covering Highly Scalable Manufacturing Process for PRF-110 Following Successful Completion and Testing

TEL AVIV, Israel, July 24, 2024 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced it has filed a patent covering its new and highly scalable manufacturing process for PRF-110, its flagship product designed to revolutionize post-operative pain control. The patent filing follows successful completion and testing of the new process. This miles

GlobeNewswire 5 months ago

PRFX
-0.63%
PainReform Completes Enrollment in the Second Part of its Phase 3 Bunionectomy Trial for PRF-110

Top line data to be reported in the second half of 2024TEL AVIV, Israel, June 26, 2024 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced a major milestone on the way to registration - the successful completion of patient enrollment in its Phase 3 clinical trial for PRF-110, a novel analgesic drug candidate designed for the treatment of post

GlobeNewswire 6 months ago

PRFX
-0.63%
PainReform Announces Receipt of Nasdaq Minimum Bid Price Notification

TEL AVIV, Israel, May 31, 2024 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced that the Company received a letter from the Nasdaq Listing Qualifications (the “Letter”), indicating that the Company is not in compliance with the minimum bid price requirement for continued listing set forth in Listing Rule 5550(a)(2), which requires listed s

GlobeNewswire 7 months ago

PRFX
-0.63%
PainReform Provides Business Update for the First Quarter of 2024

Reaches 50% enrollment in the second part of its Phase 3 clinical trial of PRF-110 in bunionectomy Remains on track to announce top-line data in Q3 2024 TEL AVIV, Israel, May 15, 2024 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today provided a business update for the first quarter ended March 31, 2024. Ilan Hadar, Chief Executive Officer of PainRefo

GlobeNewswire 7 months ago

PRFX
-0.63%

Performance Overview

Return	PRFX	S&P 500
YTD	-1.56%	-1.35%
1-Year	-81.63%	+22.51%
3-Year	-96.05%	+24.59%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

PainReform Ltd. (PRFX)

PainReform Faces Setback in Phase 3 Trial for PRF-110

PainReform Provides Further Update on Phase 3 Clinical Trial of PRF-110

PainReform Announces Initial Topline Data for PRF-110 Phase 3 Clinical Trial

PainReform Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders’ Equity Requirement

PainReform cut to Hold at Maxim amid ‘changed’ market dynamics

PainReform Ltd. Confirms Sutures Compatibility in Human Clinical Trials for PRF-110

Top Midday Decliners

PainReform Announces Exercise of Warrants for $1.58 Million Gross Proceeds

Upcoming Stock Splits This Week (September 9 to September 13) – Stay Invested

PainReform Bunionectomy Study Observations Confirm Optimal Delivery Method for PRF-110 in Bunionectomy Procedures

PainReform Announces Positive Safety Profile for PRF-110 in Phase 3 Bunionectomy Study

PainReform Provides Business Update for the Second Quarter of 2024

PainReform Announces Development and Successful Manufacturing of New Formulations Providing Anti-Inflammatory and Extended Analgesic Effects

PainReform Announces Favorable Safety Profile of PRF-110, Indicating Potential for Use in New Surgical Applications Requiring Higher Doses

PainReform Ltd. Announces Favorable Wound Healing Data in Human Clinical Trials for PRF-110

PainReform’s New Manufacturing Process Achieves Significant Benefits Including 18-Month Stability of PRF-110 at Room Temperature

PainReform Files Patent Covering Highly Scalable Manufacturing Process for PRF-110 Following Successful Completion and Testing

PainReform Completes Enrollment in the Second Part of its Phase 3 Bunionectomy Trial for PRF-110

PainReform Announces Receipt of Nasdaq Minimum Bid Price Notification

PainReform Provides Business Update for the First Quarter of 2024

Performance Overview